Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;6(3):157-9.
doi: 10.1080/21541248.2015.1018403.

Drugging the Ral GTPase

Chao Yan  1 , David N M Jones, Dan Theodorescu
Affiliations

Drugging the Ral GTPase

Chao Yan et al. Small GTPases. 2015.

Abstract

The RAL GTPases have emerged as important drivers of tumor growth and metastasis in lung, colon, pancreatic and other cancers. We recently developed the first small molecule inhibitors of RAL that exhibited antitumor activity in human lung cancer cell lines. These compounds are non-competitive inhibitors that bind to the allosteric site of GDP-bound RAL. The RAL inhibitors have the potential to be used in combination therapy with other inhibitors of the RAS signaling pathway. They also provide insights toward directly targeting other GTPases.

Keywords: GTPase; Ral; Ras; allosteric; metastasis; personalized medicine; precision medicine; small molecule; targeted therapy.

PubMed Disclaimer

References

    1. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci 2005; 118:843-6; PMID:15731001; http://dx.doi.org/10.1242/jcs.01660 - DOI - PubMed
    1. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308; PMID:17384584; http://dx.doi.org/10.1038/nrc2109 - DOI - PubMed
    1. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 2014; 13:828-51; PMID:25323927; http://dx.doi.org/10.1038/nrd4389 - DOI - PMC - PubMed
    1. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-310; PMID:17496923; http://dx.doi.org/10.1038/sj.onc.1210422 - DOI - PubMed
    1. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8:393-412; PMID:18721898; http://dx.doi.org/10.1016/j.coph.2008.08.004 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources